Since its establishment in 2023, Jierunxin Biotech Co. (hereby: Jierunxin) has been a trailblazer in medical diagnostics. Based in Rongheng Industrial Park, Huzhou City, amongst the innovative hub of Yangtze River Delta’s biomedical cluster, Jierunxin strives to continuously develop accurate and reliable diagnostic solutions in healthcare.

Guided by the principles of collaborative innovation, product excellence and global marketing, we have built a thriving enterprise that specializes in three core diagnostic platforms: Fluorescence immunochromatography, colloidal gold rapid detection and dry chemistry testing. Our portfolio includes, but is not limited to, testing for inflammation, renal function, and cardiac damage: Thus offering precise markers for cardiovascular, cerebrovascular, infectious and kidney disease. This success is due in no small part to our ever-growing industrial/academic partnerships with top tier universities as well as tertiary hospitals in Shanghai and its surrounding provinces.

Our company strictly complies with ISO 13485 Medical Device Quality Management System and YY/T 0287 Medical Device Production Standards. Our quality assurance systems encompass the full lifecycle of product development. From the selection of raw materials to the management of our products clinical application, we will continuously uphold the highest standards of quality control

At Jierunxin, our staff work diligently whilst maintaining ethical standards. Our team comprises of outstanding specialists in R&D and product management led by overseas-returned doctors and a dedicated marketing and sales team that ensures a customer centric to a global audience.

We remain committed to safeguarding your health through investigative diagnostics. By continuously advancing our products whilst maintaining rigorous quality control, we endeavour to provide dependable, precise products and services to our customers around the world.